✦ LIBER ✦

The neuroprotective and neurotrophic agent T-817MA for Alzheimer’s disease: Randomized, double-blind, placebo-controlled proof-of-concept trial outcomes

✍ Scribed by Schneider, Lon; Porsteinsson, Anton; Farlow, Martin; Shimakura, Akira; Nakagawa, Masaya; Iwakami, Noboru

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cerebrolysin in Alzheimer's disease: a r

✍ M. Panisset; S. Gauthier; H. Moessler; M. Windisch; and The Cerebrolysin Study G 📂 Article 📅 2002 🏛 Springer 🌐 English ⚖ 103 KB

Study of the ketogenic agent AC-1202 in

✍ Samuel T Henderson; Janet L Vogel; Linda J Barr; Fiona Garvin; Julie J Jones; La 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 640 KB

T1155 A Randomized Double-Blind Placebo-

✍ Sbrocchi, Anne Marie; Forget, Sylviane; Rodd, Celia 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 107 KB

A randomized, double-blind placebo-contr

✍ Cynthia M. Carlsson; Carey E. Gleason; Sterling C. Johnson; Guofan Xu; Yin Huang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB